Skip to content
info@ibsgranada.es
FacebookTwitterLinkedInInstagramYouTube
ibs logo.GRANADA
  • ibs.GRANADA
  • The Institute
    • The Institute
    • Organizational structure
    • Management Units
    • Economic information
    • Centers
    • Responsible Research and Innovation (RRI)
    • Researcher Area
    • Annual Reports ibs.GRANADA
    • Webmail access
    • Transparency
  • Research
    • Own Plan ibs.GRANADA
    • Research Areas
    • Research groups
    • Clinical research
    • Collaboration network between groups of the ibs.GRANADA
    • Researcher Finder
    • Publications Search
  • Innovation
    • Innovation
    • Technology Offers
    • Clinical practice guidelines
  • International
    • International Projects Unit
    • International Projects
    • International Networks
  • Training
    • Training
    • Research Sessions
    • Conferences and Courses
    • Mentoring Program ibs.GRANADA
    • PhD Programs
    • Official University Master's Degrees
  • Today
    • Calls for applications
    • News
    • Events
  • Job vacancies
    • Job vacancies
    • Human Resources Strategy for Researchers of the European Commission (HRS4R)
  • Digital Platforms

Ae22-Cancer Genetics, Biomarkers and Experimental Therapies (Emerging)

Oncology / IBS-Ae22 / Emerging

ibs.GRANADA  ·  Research groups
  • Information
  • Members
  • Publications
  • Projects
  • Clinical trials

The main objective of the multidisciplinary research group "CANCER GENETICS, BIOMARKERS AND EXPERIMENTAL THERAPIES" is to identify new biomarkers to improve the diagnosis, prognosis and treatment of cancer patients, through the study of new mechanisms of gene regulation, which they have been shown to be important for tumor development, and are currently at the frontier of knowledge; among which are: Chromatin remodeling complexes, and non-coding RNAs. Our group intends to transfer molecular findings to daily clinical practice, to make this possible, our multidisciplinary research group uses state-of-the-art technologies working with patient samples, public repositories of genomic data, cell lines and pre-clinical in vivo models. to validate the role of new biomarkers in cancer.

Research lines

  • Identification of new molecular biomarkers to improve the diagnosis, prognosis and treatment of cancer patients
  • Regulation of gene expression in cancer through the study of the SWI / SNFI complex and its interactions with miRNAs, lncRNAs and DNA

Keywords

Cancer, Biomarkers, Bioinformatics, Non-coding RNAs, SWI / SNF, miRNAs, lncRNAs

Juan de los Santos Jimenez

  • ORCID

SERGIO CASTRO GONZALEZ

  • ORCID

PATRICIA CONCHA MORAL

  • ORCID

ANA UTRILLA MAESTRE

FERNANDO MONTENEGRO ELVIRA

PABLO MARTIN LOPEZ

  • ORCID

ANA MARIA MATIA GONZALEZ

  • ORCID

MARIA SOLEDAD BENITEZ CANTOS

  • ORCID

ANA BELEN GAMIZ MOLINA

PEDRO MEDINA VICO

  • Request More Information
  • ORCID

FLORENCIO QUERO VALENZUELA

IMMACULADA SEGURA JIMENEZ

MARTA CUADROS CELORRIO

  • Request More Information
  • ORCID
Benitez-Cantos, M.S.; Cano, C.; Cuadros, M.; Medina, P.P.

Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma

MOLECULAR CANCER, 2024;

FI: 27,7; D1

Gómez-Gago, AM; de las Heras-Marqués, B; Quero-Valenzuela, F

Late Unexpected Pneumopericardium Due to Pleuro-pericardial Atrial Perforation by Pacemaker Lead

ARCHIVES DE BRONCONEUMOLOGIA, 2024;

FI: 8,7; D1

Núñez, JM; Benitez, JR; Valenzuela, CF; Matthew, AC; Otero, AN; Ciuró, AH; Valenza, MC

Musculoskeletal Disorders Related to Upper Limb Disability after One-Year Lung Cancer Resection

CANCER, 2024;

FI: 4,5; Q1

Heredia-Ciuró, A.; Quero-Valenzuela, F.; Martín-Núñez, J.; Calvache-Mateo, A.; Valenza-Peña, G.; López-López, L.; Valenza, M.C.

Physical Deconditioning in Lung Cancer Patients Who Underwent Lung Resection Surgery in Spain: A Prospective Observational Study

CANCER, 2024;

FI: 4,5; Q1

Santiago, MG; López, LL; Valenzuela, CF; Matthew, AC; Núñez, JM; Rubio, AO; Valenza, MC

Predictive Factors for Onset of Moderate-to-Severe Disability Following Hospital Discharge Due to Rib Fractures

HEALTHCARE, 2024;

FI: 2,4; Q2

Esposito, R; Lanzos, A; Uroda, T; Ramnarayanan, S; Buechi, I; Polidori, T; Guillen-Ramirez, H; Mihaljevic, A; Merlin, B.M.; Mela, L; Zoni, E; Hovhannisyan, L; McCluggage, F; Medo, M; Basile, G; Meise, DF; Zwyssig, S; Wenger, C; Schwarz, K; Vancura, A; bosch

Tumor mutations in long noncoding RNAs enhance cell fitness (vol 14, 3342, 2023)

NATURE COMMUNICATIONS, 2023;

FI: 16,6; D1

Esposito, R; Lanzós, A; Uroda, T; Ramnarayanan, S; Büchi, I; Polidori, T; Guillen-Ramirez, H; Mihaljevic, A; Merlin, B.M.; Mela, L; Zoni, E; Hovhannisyan, L; McCluggage, F; Medo, M; Basile, G; Meise, DF; Zwyssig, S; Wenger, C; Schwarz, K; Vancura, A; Bosch-

Tumor mutations in long noncoding RNAs enhance cell fitness

NATURE COMMUNICATIONS, 2023;

FI: 16,6; D1

Patiño-Mercau, JR; Baliñas-Gavira, C; Andrades, A; Benitez-Cantos, MS; Rot, A.E.; Rodriguez, MI; Alvarez-Perez, JC; Pictures, M; Medina, PP

BCL7A is silenced by hypermethylation to promote acute myeloid leukemia

BIOMARKER RESEARCH, 2023;

FI: 11,1; D1

Castro-Gonzalez, S; Cuadros, M; Medina, PP

Clinical applications of DNA methylation profiling in lung cancer

TRANSLATIONAL LUNG CANCER RESEARCH, 2023;

FI: 4; Q2

Lopez, I; Aguinagalde, B; Urreta, I; Royo, I; Bolufer, S; Sanchez, L; Zabaleta, J; Fernandez-Monge, A; Recuero, JL; Sesma, J; Amor, S; Moradiellos, FJ; Arraras, MJ; Blanco, AI; Boada, M; Sanchez, D; Cabañero, A; Moreno, N; Cal, I; Moreno, R; Cilleruelo, A

Results in mediastinal lymph node staging of surgical lung cancer: Data from the prospective cohort of the Spanish Video-Assisted Thoracic Surgery Group

ESPANOL SURGERY, 2023;

FI: 1,9; Q3

Gallardo, A; Molina, A; Asenjo, HG; Lopez-Onieva, L; Martorell-Marugan, J; Espinosa-Martinez, M; Grinan-Lison, C; Alvarez-Perez, JC; Face, FAITH; Navarro-Marchal, SA; Carmona-Saez, P; Medina, PP; Marchal, JA; Granados-Principal, S; Sanchez-Pozo, A; Landeira, D.

EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumor colonization

ONCOGENE, 2022;

FI: 8,756; D1

Andrades, A; Alvarez-Perez, JC; Patino-Mercau, JR; Pictures, M; Balinas-Gavira, C; Medina, PP

Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes

BLOOD, 2022;

FI: 25,476; D1

Hairstyle, P; Andrades, A; Pictures, M; Rodriguez, MI; Chur, IF; Garcia, DJ; Benitez-Cantos, MS; Cano, C; Zarzuela, E; Munoz, J; Loidi, C; Saiz, M; Medina, PP

Multi-omic alterations of the SWI/SNF complex defines a clinical subgroup in lung adenocarcinoma

CLINICAL EPIGENETICS, 2022;

FI: 7,259; Q1

Boyero, L; Martin-Padron, J; Farez-Vidal, ME; Rodriguez, MI; Andrades, A; Hairstyle, P; Arenas, AM; Ritore-Salazar, F; Alvarez-Perez, JC; Pictures, M; Medina, PP

PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer

CELLULAR ONCOLOGY, 2022;

FI: 7,051; Q1

Pictures, M; Cano, C; Garcia-Rodriguez, S; Martin, J.L.; Poyatos-Andujar, A; Ruiz-Cabello, F; Pedrinaci, S; Duran, G; Benavides, M; Bautista-Ojeda, MD; Pereda, T; Benitez-Cantos, MS; Medina, P; White, A; Gonzalez, A; Lizardi, P

Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers

BMC MEDICAL GENOMICS, 2022;

FI: 3,622; Q2

Romero, OA; Vilarrubi, A; Alburquerque-Bejar, JJ; Gomez, A; Andrades, A; Trastulli, D; Pros, E; Setien, F; Vegetables; Farre, L.; Martin-Tejera, JF; Llabata, P; Oakin, A; Saigi, M; Piulats, JM; Matias-Guiu, X; Medina, PP; Vidal, A; Villanueva, A; Sanchez-

SMARCA4 deficient tumors are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

NATURE COMMUNICATIONS, 2021;

FI: 14,919; D1

Rodriguez-Torres, J; Lopez-Lopez, L; Cabrera-Martos, I; Quero-Valenzuela, F; Cahalin, L.P.; Cebria-i-Iranzo, MD; Valenza, M.C.

Inpatient Step Counts, Symptom Severity, and Perceived Health Status After Lung Resection Surgery

CANCER NURSING, 2021;

FI: 2,592; Q1

Sanchez-Martin, V; Schneider, D.A.; Ortiz-González, M; Soriano-Lerma, A; Linde-Rodriguez, A; Perez-Carrasco, V; Gutierrez-Fernandez, J; Tables, M; González, C; Soriano, M; Garcia-Salcedo, J.A.

Targeting ribosomal G-quadruplexes with naphthalene-diimides as RNA polymerase I inhibitors for colorectal cancer treatment

CELL CHEMICAL BIOLOGY, 2021;

FI: 8,116; Q1

Hairstyle, P; Andrades, A; Martorell-Marugan, J; Haswell, JR; Slack, FJ; Carmona-Saez, P; Medina, P.P.

The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma

HUMAN MOLECULAR GENETICS, 2021;

FI: 6,15; Q1

Kiss, HJ; Rodriguez-Lara, I; Rosa-Garcia, A.

Does response time predict withdrawal decisions? Lessons from a bank-run experiment

REVIEW OF BEHAVIORAL FINANCE, 2020;

Fu, A; Alvarez-Perez, JC; Avizonis, D; Kin, T; Ficarro, S.B.; Choi, DW; Karakose, E; Badur, M.G.; Evans, L; Rosselot, C; Bridon, G; Bird, G.H.; Seo, H.S.; Dhe-Paganon, S; Kamphorst, JJ; Stewart, AF; Shapiro, AMJ; Martin, J.A.; Walensky, L.D.; Jones, R.G.; Garcia-Ocana,

Glucose-dependent partitioning of arginine to the urea cycle protects beta-cells from inflammation

NATURE METABOLISM, 2020;

Balinas-Gavira, C; Rodriguez, MI; Andrades, A; Tables, M; Alvarez-Perez, JC; Alvarez-Prado, AF; from Yebenes, VG; Sanchez-Hernandez, S; Fernandez-Vigo, E; Munoz, J; Martin, F; Ramiro, AR; Martinez-Climent, JA; Medina, PP

Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL

LEUKEMIA, 2020;

FI: 8,665; D1

Hairstyle, P; Andrades, A; Tables, M; Rodriguez, MI; Chur, IE; Garcia, DJ; Alvarez-Perez, JC; Balinas-Gavira, C; Arenas, AM; Patino-Mercau, JR; Sanjuan-Hidalgo, J; Romero, OA; Montuenga, LM; Carretero, J; Sanchez-Cespedes, M; Medina, PP

Comprehensive Analysis of SWI / SNF Inactivation in Lung Adenocarcinoma Cell Models

CANCER, 2020;

FI: 6,126; Q1

Arenas, AM; Tables, M; Andrades, A; Garcia, DJ; Chur, IF; Rodriguez, MI; Balinas-Gavira, C; Hairstyle, P; Alvarez-Perez, JC; Medina, PP

LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma

CANCER, 2020;

FI: 6,126; Q1

UNRAVELING THE THERAPEUTIC POTENTIAL OF SWI/SNF IN NUT CARCINOMA

Funder: HEALTH AND CONSUMPTION COUNCIL

File number: PI-0228-2024

Execution time: 28/11/2024 - 29/11/2027

PI: PEDRO MEDINA VICO

Preclinical evaluation of the efficacy and safety of the use of suicide genes as a personalized antitumor tool

Funder: HEALTH AND CONSUMPTION COUNCIL

File number: PIP-0173-2022

Execution time: 18/11/2022 - 17/11/2025

IP: FLORENCIO QUERO VALENZUELA

Molecular and functional characterization of new lung cancer drivers

Funder: HEALTH AND CONSUMPTION COUNCIL

File number: PI-0203-2022

Execution time: 18/11/2022 - 17/11/2025

IP: ANA MARIA MATIA GONZALEZ

Development of experimental and pre-clinical therapeutic strategies for Squamous cell carcinoma of the lung

Funder: COUNCIL OF HEALTH AND FAMILIES

File number: PIGE-0213-2020

Execution time: 28/10/2021 - 27/10/2023

PI: PEDRO MEDINA VICO

Development of experimental and pre-clinical therapeutic strategies for acute myeloid leukemia

Funder: COUNCIL OF HEALTH AND FAMILIES

File number: PI-0135-2020

Execution time: 01/01/2021 - 31/12/2023

PI: PEDRO MEDINA VICO

Efficacy of atezolizumab with concomitant radiotherapy in patients with musculo-invasive bladder cancer. ML40458

Funder: GRUPO ESPAÑOL ONCOLOGIA GENITOURINARIA (SOGUG)

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 17/01/2020 - 30/10/2026

Non-interventional, multicenter, multi-cohort study to investigate the outcomes and safety of atezolizumab treatment in real-life conditions of routine clinical practice. ROC-ATE-2018-01

Financier: ROCHE FARMA, SA

Type of test: COMMERCIAL POST AUTHORIZATION STUDY

Execution time: 30/03/2020 - 30/05/2025

Randomized, double-blind, phase II clinical trial to evaluate maintenance with olaparib versus placebo in platinum-sensitive advanced non-small cell lung cancer patients

Funder: INSTITUT GUSTAVE ROUSSY

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 06/10/2015 - 31/12/2020

Maintenance treatment with ODM-201 in patients with castration-resistant metastatic prostate cancer (mCRPC) previously treated with new hormonal agents and non-progressive disease after receiving subsequent treatment with a taxane: Phase II, multicenter, randomized, double-blind study and placebo controlled

Funder: GRUPO ESPAÑOL ONCOLOGIA GENITOURINARIA (SOGUG)

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 30/01/2019 - 30/12/2021

facebook icon twitter icon LinkedIn icon whatsapp icon

Responsible researcher

MARTA CUADROS CELORRIO

  • mcuadras@ugr.es
  • Request More Information
  • ORCID

Responsible Co-Investigator

PEDRO MEDINA VICO

  • pedro.medina@genyo.es
  • Request More Information
  • ORCID

Research

  • Collaboration network between groups of the ibs.GRANADA
  • Oncology Area
  • Epidemiology and Public Health Area
  • Precision Medicine Area
  • Advanced Therapies and Biomedical Technologies Area
  • Clinical research

Post navigation

Ae21-Epigenetics in Aging and Cancer (Emerging)
Ae23-Translational and Integrative Oncology (Emerging)

ibs.Granada logo

  • info@ibsgranada.es
  • Avda. De Madrid, 15
    External Consultation Pavilion, 2nd Floor
    18012 Grenada.
  • facebook icon
  • twitter icon
  • instagram icon
  • linkedin icon
  • youtube icon
University of Granada
Investigate +
© 2025 ibs.GRENADA
  • Legal Notice
  • Cookies Policy
  • Privacy Policy
  • Contact
  • Site map

We use cookies to offer you the best experience on our website.

You can learn more about which cookies we use or deactivate them in the .

X
ibs logo.GRANADA
Powered by  GDPR Cookie Compliance
Privacy summary

This website uses cookies so that we can offer you the best possible user experience. The information of the cookies is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.

Technical and necessary cookies

The strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

Analytics and optimization

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Cookies policy

More information about our Cookies policy